TN2011000053A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TN2011000053A1
Authority: TN; Tunisia
Prior art keywords: organic compounds; compounds; phosphatidylinositol; kinase; substituents
Prior art date: 2008-09-10

Application number

TN2011000053A

Other languages

English (en)

Inventor

Giorgio Caravatti

Pascal Furet

Robin Alec Fairhurst

Vito Guagnano

Patricia Imbach

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-10

Filing date

2011-01-31

Publication date

2012-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-31 Application filed by Novartis Ag filed Critical Novartis Ag

2012-09-05 Publication of TN2011000053A1 publication Critical patent/TN2011000053A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Virology (AREA)

TN2011000053A 2008-09-10 2011-01-31 Organic compounds TN2011000053A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08164104		2008-09-10
US9667408P	2008-09-12	2008-09-12
PCT/EP2009/061644 WO2010029082A1 (fr)	2008-09-10	2009-09-08	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2011000053A1 true TN2011000053A1 (en)	2012-09-05

Family

ID=40350060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000053A TN2011000053A1 (en)	2008-09-10	2011-01-31	Organic compounds

Country Status (50)

Country	Link
US (4)	US8227462B2 (fr)
EP (1)	EP2331537B1 (fr)
JP (1)	JP5486601B2 (fr)
KR (1)	KR101290844B1 (fr)
CN (1)	CN102149711B (fr)
AR (2)	AR073369A1 (fr)
AU (1)	AU2009290904B2 (fr)
BR (1)	BRPI0918750B8 (fr)
CA (1)	CA2734819C (fr)
CL (1)	CL2011000504A1 (fr)
CO (1)	CO6351738A2 (fr)
CR (1)	CR20110059A (fr)
CU (1)	CU24000B1 (fr)
CY (2)	CY1117078T1 (fr)
DK (1)	DK2331537T3 (fr)
DO (1)	DOP2011000070A (fr)
EA (1)	EA018863B1 (fr)
EC (1)	ECSP11010880A (fr)
ES (1)	ES2560673T3 (fr)
FI (1)	FIC20200046I1 (fr)
GE (1)	GEP20135991B (fr)
HN (1)	HN2011000699A (fr)
HR (1)	HRP20160014T1 (fr)
HU (2)	HUE025884T2 (fr)
IL (1)	IL210976A (fr)
JO (1)	JO3121B1 (fr)
LT (1)	LTC2331537I2 (fr)
LU (1)	LUC00186I2 (fr)
MA (1)	MA32604B1 (fr)
ME (1)	ME01284B (fr)
MX (1)	MX2011002597A (fr)
MY (1)	MY151556A (fr)
NI (1)	NI201100049A (fr)
NL (1)	NL301071I2 (fr)
NO (1)	NO2020037I1 (fr)
NZ (1)	NZ590754A (fr)
PA (1)	PA8841901A1 (fr)
PE (1)	PE20110796A1 (fr)
PL (1)	PL2331537T3 (fr)
PT (1)	PT2331537E (fr)
RS (1)	RS54476B1 (fr)
SI (1)	SI2331537T1 (fr)
SM (1)	SMP201100019B (fr)
SV (1)	SV2011003853A (fr)
TN (1)	TN2011000053A1 (fr)
TW (1)	TWI453206B (fr)
UA (1)	UA104147C2 (fr)
UY (1)	UY32096A (fr)
WO (1)	WO2010029082A1 (fr)
ZA (1)	ZA201100699B (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
RU2508110C2 (ru)	2008-07-11	2014-02-27	Новартис Аг	КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) *	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
KR101854484B1 (ko) *	2010-11-08	2018-05-03	노파르티스 아게	Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료에서의 2-카르복사미드 시클로아미노 우레아 유도체의 용도
AU2015203865B2 (en) *	2010-11-08	2016-11-03	Novartis Ag	Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
UA112539C2 (uk)	2011-03-03	2016-09-26	Новартіс Аг	Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
PH12013502077A1 (en) *	2011-04-25	2013-12-16	Novartis Ag	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
RU2014101626A (ru) *	2011-06-21	2015-07-27	Новартис Аг	Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
PE20141381A1 (es)	2011-07-01	2014-10-21	Novartis Ag	Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
WO2013066483A1 (fr)	2011-08-31	2013-05-10	Novartis Ag	Combinaisons synergiques d'inhibiteurs de pi3k et de mek
WO2013049581A1 (fr) *	2011-09-30	2013-04-04	Beth Israel Deaconess Medical Center Inc.	Compositions et méthodes de traitement de maladies de prolifération
JP6180420B2 (ja) *	2011-10-14	2017-08-16	ノバルティスアーゲー	増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
CN103889422A (zh) *	2011-10-28	2014-06-25	诺华股份有限公司	治疗胃肠道间质瘤的方法
AU2012331125A1 (en)	2011-11-02	2014-05-22	Novartis Ag	2-carboxamide cycloamino urea derivatives for use in treating VEGF - dependent diseases
RU2627701C2 (ru) *	2012-02-22	2017-08-10	Сэнфорд-Бёрнхэм Медикал Рисёрч Инститьют	Сульфонамидные соединения и их применение в качестве ингибиторов tnap
ES2845560T3 (es)	2012-03-29	2021-07-27	Novartis Ag	Diagnóstico farmacéutico
CA2865993A1 (fr)	2012-03-30	2013-10-03	Novartis Ag	Composes pour utilisation dans le traitement de neuroblastome, sarcome d'ewing ou un rhabdomyosarcome
KR20160027217A (ko)	2012-05-23	2016-03-09	에프. 호프만-라 로슈 아게	내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8980259B2 (en) *	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
US9474754B2 (en) *	2012-08-07	2016-10-25	Novartis Ag	Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
ES2901712T3 (es) *	2012-08-16	2022-03-23	Novartis Ag	Combinación de un inhibidor de pi3k y un inhibidor de c-met.
JP6212563B2 (ja) *	2012-09-20	2017-10-11	ノバルティスアーゲー	ホスファチジルイノシトール３−キナーゼ阻害剤およびアロマターゼ阻害剤を含む組合せ医薬
SG11201503628YA (en) *	2012-11-16	2015-06-29	Merck Patent Gmbh	3-aminocyclopentane carboxamide derivatives
EP3251673A1 (fr)	2012-12-13	2017-12-06	IP Gesellschaft für Management mbH	Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
BR112015017331B1 (pt)	2013-01-23	2022-01-11	Astrazeneca Ab	Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição
US20160143910A1 (en)	2013-03-15	2016-05-26	Constellation Pharmaceuticals, Inc.	Methods of treating cancer and preventing cancer drug resistance
PE20151785A1 (es) *	2013-03-21	2015-12-20	Novartis Ag	Terapia de combinacion
US20160030440A1 (en) *	2013-04-05	2016-02-04	Sanofi	Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
EP3003377A1 (fr)	2013-05-31	2016-04-13	Novartis AG	Polythérapie comprenant un inhibiteur pi3k-alpha et un inhibiteur de kinase fgfr pour traiter le cancer
CA2912346A1 (fr)	2013-06-11	2014-12-18	Novartis Ag	Combinaisons pharmaceutiques d'un inhibiteur de pi3k et d'un destabilisateur de microtubule
WO2014203152A1 (fr)	2013-06-18	2014-12-24	Novartis Ag	Combinaisons pharmaceutiques
BR112016002311A2 (pt)	2013-08-08	2017-08-01	Novartis Ag	combinações de inibidor de cinase de pim
DK3033086T3 (da)	2013-08-14	2022-01-03	Novartis Ag	Kombinationsterapi til behandling af cancer
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
HUE057092T2 (hu) *	2013-12-06	2022-04-28	Novartis Ag	Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje
RU2020121929A (ru) *	2014-01-15	2020-07-13	Новартис Аг	Фармацевтические комбинации
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170165246A1 (en)	2014-02-11	2017-06-15	Novartis Ag	Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
PH12016501545B1 (en)	2014-03-14	2023-12-06	Immutep Sas	Antibody molecules to lag-3 and uses thereof
WO2016040880A1 (fr)	2014-09-13	2016-03-17	Novartis Ag	Thérapies combinées d'inhibiteurs d'alk
WO2016051374A1 (fr)	2014-10-03	2016-04-07	Novartis Ag	Compositions pharmaceutiques contenant de l'alpélisib
EP3662903A3 (fr)	2014-10-03	2020-10-14	Novartis AG	Polythérapies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR102513870B1 (ko)	2014-10-14	2023-03-23	노파르티스 아게	Pd-l1에 대한 항체 분자 및 그의 용도
CN104844589B (zh) *	2014-12-26	2018-04-20	中国科学院合肥物质科学研究院	一种pi3k激酶抑制剂
EP3268035A4 (fr)	2015-03-10	2018-10-31	Aduro Biotech, Inc.	Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
JP2018509448A (ja) *	2015-03-25	2018-04-05	ノバルティスアーゲー	組合せ医薬
WO2017001362A1 (fr)	2015-06-29	2017-01-05	F. Hoffmann-La Roche Ag	Méthodes de traitement avec du tasélisib
PE20211775A1 (es)	2015-07-02	2021-09-08	Hoffmann La Roche	Compuestos de benzoxacepina oxazolidinona y metodos de uso
EP3964528A1 (fr)	2015-07-29	2022-03-09	Novartis AG	Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
CN108025051B (zh)	2015-07-29	2021-12-24	诺华股份有限公司	包含抗pd-1抗体分子的联合疗法
EP3316902A1 (fr)	2015-07-29	2018-05-09	Novartis AG	Polythérapies comprenant des molécules d'anticorps contre tim -3
EP3341023A1 (fr)	2015-08-28	2018-07-04	Novartis AG	Polythérapie utilisant un inhibiteur de pi3k et un inhibiteur de mdm2
WO2017037574A1 (fr)	2015-08-28	2017-03-09	Novartis Ag	Combinaisons de l'inhibiteur de cdk4/6 lee011 et de l'inhibiteur de mek1/2 trametinib, comprenant éventuellement en outre l'inhibiteur de pi3k byl719 pour traiter le cancer
CN108348520A (zh)	2015-08-28	2018-07-31	诺华股份有限公司	Mdm2抑制剂和其组合
WO2017037575A1 (fr)	2015-08-28	2017-03-09	Novartis Ag	Combinaison pharmaceutique comprenant l'inhibiteur de pi3k alpelisib et l'inhibiteur de cdk4/6 ribociclib et son utilisation dans le traitement/la prévention du cancer
US20180256557A1 (en)	2015-08-28	2018-09-13	Giordano Caponigro	Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
WO2017037587A1 (fr)	2015-08-28	2017-03-09	Novartis Ag	Combinaison de ribociclid et de dabrafenib pour le traitement ou la prévention du cancer
TW201726140A (zh)	2015-09-17	2017-08-01	瑞典商阿斯特捷利康公司	治療癌症之新型生物標記及方法
CN105294546B (zh) *	2015-10-29	2017-12-08	天津市斯芬克司药物研发有限公司	一种吡啶化合物及其制备方法
AU2016347881A1 (en)	2015-11-02	2018-05-10	Novartis Ag	Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
EP4046655A1 (fr)	2015-11-03	2022-08-24	Janssen Biotech, Inc.	Anticorps se liant spécifiquement à pd-1 et leurs utilisations
US20180353515A1 (en)	2015-12-03	2018-12-13	Novartis Ag	Treatment of cancer with a pi3k inhibitor in a patient presselected for having a pik3ca mutation in the ctdna
JP2019503349A (ja)	2015-12-17	2019-02-07	ノバルティスアーゲー	Ｐｄ−１に対する抗体分子およびその使用
EP3507367A4 (fr)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
WO2018060833A1 (fr)	2016-09-27	2018-04-05	Novartis Ag	Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
WO2018092064A1 (fr)	2016-11-18	2018-05-24	Novartis Ag	Combinaisons d'inhibiteurs de mdm2 et d'inhibiteurs de bcl-xl
CN106674200B (zh) *	2016-12-21	2019-04-12	西安交通大学	一种含有l-脯氨酰胺片段的化合物及其制备方法和应用
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (fr)	2017-06-22	2020-04-29	Novartis AG	Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
MA49457A (fr)	2017-06-22	2020-04-29	Novartis Ag	Molécules d'anticorps se liant à cd73 et leurs utilisations
EP3694511A1 (fr)	2017-10-13	2020-08-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polythérapie du cancer du pancréas
EP3713963A1 (fr)	2017-11-23	2020-09-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Nouveau marqueur permettant de prédire la sensibilité à des inhibiteurs de pi3k
JP2021504384A (ja)	2017-12-01	2021-02-15	ノバルティスアーゲー	Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ
KR102716244B1 (ko) *	2017-12-08	2024-10-14	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN112074505B (zh)	2018-03-08	2024-04-05	因赛特公司	作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
AU2019276514B2 (en)	2018-05-30	2023-12-14	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
WO2020010003A1 (fr)	2018-07-02	2020-01-09	Incyte Corporation	DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
WO2020053125A1 (fr) *	2018-09-10	2020-03-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés de traitement de la neurofibromatose
EP3860597A4 (fr)	2018-10-05	2022-08-17	Sloan-Kettering Institute for Cancer Research	Inhibiteurs de pi3k et leurs utilisations
EP3903828A4 (fr)	2018-12-21	2022-10-05	Daiichi Sankyo Company, Limited	Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase
KR20220008313A (ko)	2019-05-13	2022-01-20	뤄신 헬스케어 사이언스 앤드 테크놀로지 디벨롭먼트 (베이징) 리미티드	퀴나졸리논계 화합물의 결정형 및 이의 제조방법
CN111995541B (zh) *	2019-05-27	2025-05-06	君实润佳(上海)医药科技有限公司	含有稳定重同位素的酰胺官能团的化合物及其应用
WO2021001431A1 (fr)	2019-07-02	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Utilisation d'inhibiteurs sélectifs de pi3ka pour traiter une maladie métastatique chez des patients souffrant de cancer du pancréas
WO2021001426A1 (fr)	2019-07-02	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Utilisation d'une imagerie d'élasticité ultrarapide pour la détection de cancers du pancréas
US20220354863A1 (en)	2019-07-02	2022-11-10	Inserm (Institut National De La Santè Et De La Recherch Médicale)	Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
WO2021007146A1 (fr)	2019-07-07	2021-01-14	Olema Pharmaceuticals, Inc.	Régimes d'antagonistes du récepteur des oestrogènes
IL290789B2 (en)	2019-08-26	2025-09-01	Arvinas Operations Inc	Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
EP4031578A1 (fr)	2019-09-18	2022-07-27	Novartis AG	Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
CA3159094A1 (fr)	2019-11-25	2021-06-03	Shanghai Hansoh Biomedical Co., Ltd.	Sel ou forme cristalline contenant un derive a trois cycles fusionnes et composition pharmaceutique associee
CN113045564B (zh) *	2019-12-27	2024-09-20	上海天慈国际药业有限公司	一种阿培利司的制备方法
US12365675B2 (en)	2020-03-25	2025-07-22	Risen (Suzhou) Pharma Tech Co., Ltd.	Stable heavy isotopes in amide functional groups and uses thereof
WO2022016420A1 (fr) *	2020-07-22	2022-01-27	罗欣药业(上海)有限公司	Forme cristalline d'un composé quinazolinone, son procédé de préparation et son utilisation
WO2022234408A1 (fr)	2021-05-03	2022-11-10	Novartis Ag	Formulation d'alpélisib
CN115611883B (zh) *	2021-07-13	2025-03-28	生物岛实验室	一种双环结构的PI3Kα抑制剂及其制备方法和用途
EP4412716A4 (fr)	2021-10-05	2025-08-13	Mirati Therapeutics Inc	Combinaisons d'inhibiteurs de kras g12d et d'inhibiteurs de pi3ka et procédés de traitement associés
WO2023083330A1 (fr) *	2021-11-12	2023-05-19	百极优棠(广东)医药科技有限公司	Inhibiteur de drak2, son procédé de préparation et son utilisation
EP4230196A1 (fr)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Composés à utiliser dans le traitement des dystrophinopathies
EP4608509A1 (fr)	2022-10-28	2025-09-03	Institut National de la Santé et de la Recherche Médicale	Nouveaux inhibiteurs de la phosphatidylinositol 3-kinase
EP4615431A1 (fr)	2022-11-11	2025-09-17	Astrazeneca AB	Polythérapies pour le traitement du cancer
CN116239591B (zh) *	2023-02-14	2025-09-23	嘉兴大学	一种(4r)-磺酰氨基-l-脯氨酰胺类化合物、制备方法、应用及其药物组合
TW202440096A (zh)	2023-03-24	2024-10-16	美商亞文納營運公司	雌激素受體降解劑之給藥方案
CN116987072A (zh) *	2023-07-27	2023-11-03	武汉呈瑞生物医药科技有限公司	化合物及其应用
WO2025181153A1 (fr)	2024-03-01	2025-09-04	F. Hoffmann-La Roche Ag	Utilisation d'inhibiteurs d'atr en combinaison avec des inhibiteurs de pi3k alpha
EP4643858A1 (fr) *	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Procédés et composition pharmaceutique pour le traitement d'une maladie utérine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4649146A (en)	1983-01-31	1987-03-10	Fujisawa Pharmaceutical Co., Ltd.	Thiazole derivatives and pharmaceutical composition comprising the same
DE3703435A1 (de)	1987-02-05	1988-08-18	Thomae Gmbh Dr K	Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0373226B1 (fr)	1988-04-15	1994-06-15	Taiho Pharmaceutical Company, Limited	Composés de carbamoyle-2-pyrrolidinone
US5028726A (en) *	1990-02-07	1991-07-02	The University Of Vermont And State Agricultural College	Platinum amine sulfoxide complexes
US5780653A (en) *	1995-06-07	1998-07-14	Vivorx Pharmaceuticals, Inc.	Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
JP2001505585A (ja)	1996-12-16	2001-04-24	藤沢薬品工業株式会社	新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US6187797B1 (en)	1996-12-23	2001-02-13	Dupont Pharmaceuticals Company	Phenyl-isoxazoles as factor XA Inhibitors
US6387638B1 (en) *	1997-02-10	2002-05-14	Genentech, Inc.	Heregulin variants
WO1999021555A2 (fr)	1997-10-27	1999-05-06	Takeda Chemical Industries, Ltd.	Antagonistes des recepteurs de l'adenosine a¿3?
JP2002518380A (ja)	1998-06-18	2002-06-25	ブリストル−マイヤーズスクイブカンパニー	サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
DE60023926T2 (de)	1999-09-10	2006-07-20	Merck & Co., Inc.	Tyrosin kinase inhibitoren
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
CN100355751C (zh)	2000-03-29	2007-12-19	西克拉塞尔有限公司	2－取代的4－杂芳基－嘧啶、其组合物及其用途
JP3712393B2 (ja)	2000-10-20	2005-11-02	エーザイ株式会社	含窒素芳香環誘導体
ES2254611T3 (es)	2001-05-11	2006-06-16	Pfizer Products Inc.	Derivados de tiazol.
HUP0401748A3 (en)	2001-08-13	2011-03-28	Janssen Pharmaceutica Nv	2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
WO2003015778A1 (fr)	2001-08-17	2003-02-27	Merck & Co., Inc.	Inhibiteurs de tyrosine kinase
MXPA04002914A (es)	2001-09-28	2005-06-20	Cyclacel Ltd	N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
PE20030968A1 (es) *	2002-02-28	2004-01-12	Novartis Ag	Derivados de 5-feniltiazol como inhibidores de cinasas
AR043057A1 (es)	2002-10-30	2005-07-13	Vertex Pharma	Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
EP1567487A4 (fr)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
AU2004204778B2 (en) *	2003-01-10	2008-05-22	Threshold Pharmaceuticals, Inc.	Treatment of cancer with 2-deoxyglucose
GB0305152D0 (en)	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
CA2537841A1 (fr)	2003-09-06	2005-03-24	Vertex Pharmaceuticals Incorporated	Modulateurs de transporteurs a cassette de liaison a l'atp
EP1709019B1 (fr)	2004-01-12	2007-08-08	Applied Research Systems ARS Holding N.V.	Dérivés de thiatole et leur utilisation
EP1768982A2 (fr) *	2004-06-29	2007-04-04	Amgen Inc.	Pyrrolo[2, 3-d] pyrimidines qui modulent l'activite ack1 et lck
SE0402735D0 (sv) *	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
PT2301531T (pt) *	2005-02-18	2018-07-30	Abraxis Bioscience Llc	Combinações e modos de administração de agentes terapêuticos e terapia de combinação
DE102005024157A1 (de)	2005-05-23	2006-11-30	Amedo Gmbh	Nadelpositioniersystem
EA014350B1 (ru)	2005-05-24	2010-10-29	Мерк Сероно С.А.	Производные тиазола и их применение
AU2006251159B2 (en)	2005-05-24	2011-09-22	Merck Serono Sa	Thiazole derivatives and use thereof
DE102005024790A1 (de)	2005-05-26	2006-12-07	Eos Gmbh Electro Optical Systems	Strahlungsheizung zum Heizen des Aufbaumaterials in einer Lasersintervorrichtung
US7655446B2 (en)	2005-06-28	2010-02-02	Vertex Pharmaceuticals Incorporated	Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de)	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
CN101331125A (zh)	2005-12-12	2008-12-24	健亚生物科技公司	N-(5-元杂芳香环)-酰胺基抗病毒化合物
GB0525671D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
AU2007206860A1 (en) *	2006-01-23	2007-07-26	Laboratoires Serono S.A.	Thiazole derivatives and use thereof
US20070259855A1 (en)	2006-04-06	2007-11-08	Udo Maier	Thiazolyl-dihydro-indazole
JP2009535386A (ja) *	2006-05-03	2009-10-01	アストラゼネカアクチボラグ	チアゾール誘導体および抗腫瘍剤としてのその使用
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
FR2904190B1 (fr)	2006-07-25	2008-12-12	Inst Rech Pour Le Dev I R D Et	Utilisation d'inocula fongiques pour l'amelioration de la production maraichere
TW200827368A (en)	2006-11-21	2008-07-01	Genelabs Tech Inc	Amido anti-viral compounds
WO2008124000A2 (fr)	2007-04-02	2008-10-16	Ligand Pharmaceuticals Incorporated	Dérivés de thiazole utilisés comme composés modulateurs de récepteurs d'androgènes
RU2479577C2 (ru)	2007-05-25	2013-04-20	Эбботт Гмбх Унд Ко.Кг	Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2)
WO2009003009A1 (fr)	2007-06-26	2008-12-31	Enanta Pharmaceuticals, Inc.	Pyrrolidine substituée utilisée en tant qu'agent anti-infectieux
AU2008275891B2 (en)	2007-07-19	2013-10-10	H.Lundbeck A/S	5-membered heterocyclic amides and related compounds
WO2009080694A1 (fr)	2007-12-20	2009-07-02	Novartis Ag	Dérivés de thiazole utilisés comme inhibiteur de la pi 3 kinase
ITMI20072396A1 (it)	2007-12-20	2009-06-21	Dachi S R L	"apparato di chiusura di contenitori di materiale biologico"
JP2011506563A (ja)	2007-12-20	2011-03-03	ノバルティスアーゲー	ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

2009
- 2009-08-09 UA UAA201102837A patent/UA104147C2/uk unknown
- 2009-09-08 EP EP09782777.8A patent/EP2331537B1/fr active Active
- 2009-09-08 GE GEAP200912132A patent/GEP20135991B/en unknown
- 2009-09-08 EA EA201100447A patent/EA018863B1/ru active Protection Beyond IP Right Term
- 2009-09-08 KR KR1020117005524A patent/KR101290844B1/ko active Active
- 2009-09-08 UY UY0001032096A patent/UY32096A/es active IP Right Grant
- 2009-09-08 AR ARP090103437A patent/AR073369A1/es not_active Application Discontinuation
- 2009-09-08 HU HUE09782777A patent/HUE025884T2/en unknown
- 2009-09-08 PE PE2011000591A patent/PE20110796A1/es active IP Right Grant
- 2009-09-08 MY MYPI20110510 patent/MY151556A/en unknown
- 2009-09-08 RS RS20150860A patent/RS54476B1/sr unknown
- 2009-09-08 HR HRP20160014TT patent/HRP20160014T1/hr unknown
- 2009-09-08 JP JP2011526479A patent/JP5486601B2/ja active Active
- 2009-09-08 CA CA2734819A patent/CA2734819C/fr active Active
- 2009-09-08 WO PCT/EP2009/061644 patent/WO2010029082A1/fr not_active Ceased
- 2009-09-08 BR BRPI0918750A patent/BRPI0918750B8/pt active IP Right Grant
- 2009-09-08 DK DK09782777.8T patent/DK2331537T3/en active
- 2009-09-08 ME MEP-2011-21A patent/ME01284B/fr unknown
- 2009-09-08 SI SI200931344T patent/SI2331537T1/sl unknown
- 2009-09-08 AU AU2009290904A patent/AU2009290904B2/en active Active
- 2009-09-08 PT PT97827778T patent/PT2331537E/pt unknown
- 2009-09-08 NZ NZ590754A patent/NZ590754A/xx unknown
- 2009-09-08 CN CN200980135415.7A patent/CN102149711B/zh active Active
- 2009-09-08 ES ES09782777.8T patent/ES2560673T3/es active Active
- 2009-09-08 MX MX2011002597A patent/MX2011002597A/es active IP Right Grant
- 2009-09-08 PL PL09782777T patent/PL2331537T3/pl unknown
- 2009-09-09 TW TW098130412A patent/TWI453206B/zh active
- 2009-09-09 JO JOP/2009/0334A patent/JO3121B1/ar active
- 2009-09-10 PA PA20098841901A patent/PA8841901A1/es unknown
- 2009-09-10 US US12/556,964 patent/US8227462B2/en active Active
2011
- 2011-01-27 ZA ZA2011/00699A patent/ZA201100699B/en unknown
- 2011-01-31 TN TN2011000053A patent/TN2011000053A1/fr unknown
- 2011-01-31 IL IL210976A patent/IL210976A/en active IP Right Grant
- 2011-02-01 CR CR20110059A patent/CR20110059A/es unknown
- 2011-03-01 MA MA33661A patent/MA32604B1/fr unknown
- 2011-03-07 DO DO2011000070A patent/DOP2011000070A/es unknown
- 2011-03-08 HN HN2011000699A patent/HN2011000699A/es unknown
- 2011-03-09 NI NI201100049A patent/NI201100049A/es unknown
- 2011-03-09 CL CL2011000504A patent/CL2011000504A1/es unknown
- 2011-03-10 CU CU2011000052A patent/CU24000B1/es active IP Right Grant
- 2011-03-10 SV SV2011003853A patent/SV2011003853A/es unknown
- 2011-03-10 EC EC2011010880A patent/ECSP11010880A/es unknown
- 2011-03-17 CO CO11033546A patent/CO6351738A2/es active IP Right Grant
- 2011-04-07 SM SM201100019T patent/SMP201100019B/it unknown
2012
- 2012-06-05 US US13/488,589 patent/US8476268B2/en active Active
2013
- 2013-05-24 US US13/901,930 patent/US8710085B2/en active Active
2014
- 2014-02-27 US US14/192,633 patent/US20140186469A1/en not_active Abandoned
2015
- 2015-12-29 CY CY20151101197T patent/CY1117078T1/el unknown
2018
- 2018-06-06 AR ARP180101520A patent/AR112074A2/es not_active Application Discontinuation
2020
- 2020-11-06 NL NL301071C patent/NL301071I2/nl unknown
- 2020-11-16 NO NO2020037C patent/NO2020037I1/no unknown
- 2020-11-18 HU HUS2000044C patent/HUS2000044I1/hu unknown
- 2020-11-20 LU LU00186C patent/LUC00186I2/fr unknown
- 2020-11-24 CY CY2020037C patent/CY2020037I2/el unknown
- 2020-11-25 LT LTPA2020534C patent/LTC2331537I2/lt unknown
- 2020-11-26 FI FIC20200046C patent/FIC20200046I1/fi unknown

Also Published As

Publication number	Publication date
DK2331537T3 (en)	2016-01-25
HUE025884T2 (en)	2016-05-30
CY2020037I1 (el)	2021-03-12
AU2009290904A1 (en)	2010-03-18
BRPI0918750B8 (pt)	2021-05-25
EA018863B1 (ru)	2013-11-29
RS54476B1 (sr)	2016-06-30
IL210976A (en)	2014-09-30
LTPA2020534I1 (lt)	2020-12-28
BRPI0918750A2 (pt)	2020-08-04
US8476268B2 (en)	2013-07-02
BRPI0918750B1 (pt)	2020-12-22
SI2331537T1 (sl)	2016-02-29
TW201014851A (en)	2010-04-16
ME01284B (fr)	2013-06-20
TWI453206B (zh)	2014-09-21
US20140186469A1 (en)	2014-07-03
GEP20135991B (en)	2013-12-25
CY1117078T1 (el)	2017-04-05
CU20110052A7 (es)	2011-12-28
MY151556A (en)	2014-06-13
LUC00186I2 (fr)	2024-07-01
PL2331537T3 (pl)	2016-06-30
CO6351738A2 (es)	2011-12-20
SV2011003853A (es)	2011-05-16
CU24000B1 (es)	2014-06-27
CN102149711A (zh)	2011-08-10
SMAP201100019A (it)	2011-05-06
IL210976A0 (en)	2011-04-28
AU2009290904B2 (en)	2012-08-30
HK1156305A1 (en)	2012-06-08
DOP2011000070A (es)	2011-03-31
KR20110038737A (ko)	2011-04-14
HN2011000699A (es)	2013-12-02
NZ590754A (en)	2012-08-31
AR112074A2 (es)	2019-09-18
ZA201100699B (en)	2012-08-29
JP5486601B2 (ja)	2014-05-07
PT2331537E (pt)	2016-03-03
ES2560673T3 (es)	2016-02-22
PA8841901A1 (es)	2010-06-28
NL301071I1 (nl)	2020-11-11
CR20110059A (es)	2011-03-28
MA32604B1 (fr)	2011-09-01
AR073369A1 (es)	2010-11-03
NO2020037I1 (no)	2020-11-16
JO3121B1 (ar)	2017-09-20
EA201100447A1 (ru)	2011-10-31
CA2734819A1 (fr)	2010-03-18
US8227462B2 (en)	2012-07-24
MX2011002597A (es)	2011-07-21
US20140005232A1 (en)	2014-01-02
FIC20200046I1 (fi)	2020-11-26
EP2331537A1 (fr)	2011-06-15
HUS2000044I1 (hu)	2020-12-28
WO2010029082A1 (fr)	2010-03-18
CN102149711B (zh)	2014-09-10
SMP201100019B (it)	2012-01-18
HRP20160014T1 (hr)	2016-02-12
JP2012502080A (ja)	2012-01-26
PE20110796A1 (es)	2011-11-04
NI201100049A (es)	2011-07-26
US20100105711A1 (en)	2010-04-29
UY32096A (es)	2010-04-30
NL301071I2 (nl)	2020-12-01
CY2020037I2 (el)	2021-03-12
EP2331537B1 (fr)	2015-10-28
LTC2331537I2 (lt)	2022-01-10
KR101290844B1 (ko)	2013-07-29
CL2011000504A1 (es)	2011-07-15
UA104147C2 (uk)	2014-01-10
ECSP11010880A (es)	2011-04-29
US8710085B2 (en)	2014-04-29
US20120263712A1 (en)	2012-10-18
CA2734819C (fr)	2017-10-24

Publication	Publication Date	Title
TN2011000053A1 (en)	2012-09-05	Organic compounds
TN2010000293A1 (en)	2011-11-11	Thiazole derivatives used as pi 3 kinase inhibitors
MX2012000177A (es)	2012-02-28	2-carboxamida-cicloamino-ureas sustituidas.
TN2010000038A1 (en)	2011-09-26	Organic compounds
EP3586631A3 (fr)	2020-03-18	Composition pour la santé des plantes
NZ597517A (en)	2014-04-30	5-fluoropyrimidinone derivatives
PH12015501585A1 (en)	2015-09-21	Manufacturing process for pyrimidine derivatives
UA107445C2 (uk)	2015-01-12	5-фторпіримідинові похідні як фунгіциди
MY164776A (en)	2018-01-30	Heterocyclic compound
WO2009080705A3 (fr)	2009-09-24	Composés organiques
MX2010004493A (es)	2010-06-11	Compuestos de tropano.
NZ597570A (en)	2014-04-30	N1-acyl-5-fluoropyrimidinone derivatives
WO2011047055A8 (fr)	2012-05-24	Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
MX2008016358A (es)	2009-01-16	Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
MX2012000178A (es)	2012-02-28	2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
MX2013002620A (es)	2013-05-09	Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
JO2999B1 (ar)	2016-09-05	مركب ثلاثي حلقي و استخدامه الدوائي
NZ591837A (en)	2013-03-28	Amino acid derivative
GB0602951D0 (en)	2006-03-29	Organic Compounds
NZ590076A (en)	2012-11-30	Treating plexiform neurofibroma and related tumors
NZ599916A (en)	2013-10-25	5-amino-4-hydroxypentoyl amides
ATE522530T1 (de)	2011-09-15	2-piperazin-1-yl-3h-imidazoä4,5-bü- pyridinderivate
MX2011012511A (es)	2012-02-28	Anti-oomicetos.